Adage Capital Partners Gp, L.L.C. Madrigal Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$54.9 Billion
Q4 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 19,960 shares of MDGL stock, worth $6.54 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

19,960

Holding current value

$6.54 Million

% of portfolio

0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$202.45 - $354.85 $4.04 Million - $7.08 Million	19,960 New	19,960 $6.16 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $1.71 Million - $2.83 Million	10,000 New	10,000 $2.67 Million
Q2 2023 Aug 14, 2023	SELL	$203.88 - $312.0 $11.4 Million - $17.5 Million	-56,000 Reduced 52.83%	50,000 $11.6 Million
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $4.25 Million - $5.65 Million	-18,391 Reduced 14.78%	106,000 $25.7 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $6.73 Million - $34.2 Million	115,291 Added 1266.93%	124,391 $36.1 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $551,187 - $723,541	9,100 New	9,100 $591,000
Q2 2022 Aug 15, 2022	SELL	$58.04 - $100.2 $4.49 Million - $7.75 Million	-77,331 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $1.27 Million - $2.31 Million	-22,669 Reduced 22.67%	77,331 $7.59 Million
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $3.66 Million - $5.18 Million	37,677 Added 60.45%	100,000 $9.74 Million
Q1 2021 May 17, 2021	BUY	$108.54 - $125.2 $6.76 Million - $7.8 Million	62,323 New	62,323 $7.29 Million
Q1 2020 May 15, 2020	SELL	$66.76 - $93.49 $2.67 Million - $3.74 Million	-40,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$84.28 - $118.5 $3.37 Million - $4.74 Million	40,000 New	40,000 $3.64 Million
Q2 2019 Aug 14, 2019	SELL	$91.13 - $142.5 $2.92 Million - $4.57 Million	-32,050 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$103.48 - $143.84 $517,400 - $719,200	-5,000 Reduced 13.5%	32,050 $4.02 Million
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $473,850 - $1.08 Million	5,000 Added 15.6%	37,050 $4.18 Million
Q3 2018 Nov 14, 2018	SELL	$207.3 - $300.31 $3.72 Million - $5.39 Million	-17,950 Reduced 35.9%	32,050 $6.86 Million
Q2 2018 Aug 14, 2018	SELL	$101.55 - $313.9 $20.3 Million - $62.8 Million	-200,000 Reduced 80.0%	50,000 $14 Million
Q1 2018 May 15, 2018	SELL	$93.35 - $149.04 $18.8 Million - $30 Million	-201,500 Reduced 44.63%	250,000 $29.2 Million
Q4 2017 Feb 14, 2018	SELL	$39.35 - $97.37 $1.91 Million - $4.72 Million	-48,500 Reduced 9.7%	451,500 $41.4 Million
Q3 2017 Nov 14, 2017	BUY	$15.48 - $46.19 $7.74 Million - $23.1 Million	500,000	500,000 $22.5 Million

Others Institutions Holding MDGL

# of Institutions

337

Shares Held

22.3M

Call Options Held

960K

Put Options Held

940K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.61B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Madrigal Pharmaceuticals, Inc. Transaction History